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Background and purposes: Early biomarkers of tumour response are needed to discriminate between
responders and non-responders to radiotherapy. We evaluated the ability of ceramide, a bioactive sphin-
golipid, to predict tumour sensitivity in patients treated by hypofractionated stereotactic body radiation
therapy (SBRT) combined with irinotecan chemotherapy.
Materials and methods: Plasma levels of total ceramide and of its subspecies were measured before and
during treatment in 35 patients with liver and lung oligometastases of colorectal cancer included in a
phase II trial. Cer levels were quantified by LC–ESI-MS/MS and compared to tumour volume response
evaluated one year later by CT-scan.
Results: Pretreatment plasma ceramide levels were not indicative of tumour response. Nevertheless, the
levels of total ceramide and of its 4 main subspecies were significantly higher at days 3 and 10 of treat-
ment in objective responders than in non-responders. According to Kaplan–Meier curves, almost com-
plete tumour control was achieved at 1 year in patients with increased total ceramide levels whereas
50% of patients with decreased levels experienced an increase in tumour volume.
Conclusions: Total plasma ceramide is a promising biomarker of tumour response to SBRT combined with
irinotecan that should enable to segregate patients with high risk of tumour escape.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 229–235
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Radiation therapy is a common palliative and curative anti-
cancer treatment but its efficacy is limited by intrinsic tumour
resistance to radiation [1]. The development of stereotactic body
radiation therapy (SBRT) has led to better tumour targeting and
to the delivery of higher radiation doses in a limited number of
fractions [2]. However, the efficacy of SBRT in reducing oligometas-
tases and small solid tumours needs to be assessed for all tumours
depending upon its resistance, size and location, usually by mea-
suring tumour volume by non-invasive imaging techniques, such
as CT-scan, MRI, or PET-scan. Since the response of the tumour is
generally detected long after the end of radiotherapy, with late
radiological modifications after SBRT being particularly difficult
to assess [3], there is a real risk of prolonged unnecessary andineffective exposure to radiation and of delays in initiating alterna-
tive treatments.
The availability of biomarkers that distinguish between
responding and refractory patients early during the course of
radiotherapy would represent a major clinical advance to define
patients with high risk of tumour escape to the treatment. A poten-
tially interesting biomarker is ceramide (Cer), a pro-apoptotic sph-
ingolipid generated rapidly after irradiation. Cer is produced in the
outermost layer of the cell membrane on hydrolysis of sphin-
gomyelin by acidic sphingomyelinase (ASM) or neutral sphin-
gomyelinase (NSM) and is synthetized de novo in endoplasmic
reticulum by Cer synthase [4]. Adding exogenous Cer to
androgen-sensitive human prostate adenocarcinoma cells (LNCAP
cells) enhanced cell radiosensitivity and tumour regression [5].
Increasing endogenous Cer in human T lymphocyte cells (Jurkat
cells) by the action of inhibitors of glucosyl-Cer synthase and
ceramidase inhibitors (DL-PDMP and D-MAPP, respectively)
230 Plasma ceramide correlates with SBRT efficacyalso enhanced cell radiosensitivity [6]. Cer induced by high dose
irradiation provoked massive endothelial cell apoptosis via ASM
activation, and regression of fibrosarcoma or melanoma trans-
planted in wild-type mice [7].
Elevated Cer levels have been observed in plasma and serum
from patients with lung emphysema [8], Wilson disease [9] and
multiple organ failure [10]. Plasma Cer levels increased during lipid
infusion in humans and rats, and were correlated with insulin sen-
sitivity, inflammation and atherosclerotic risk [11]. Increased Cer
serum levels were recorded after 3 days of treatment in 5 of 7
patients who responded to spatial fractionated grid radiotherapy
(SFGRT) including a first irradiation at 15 Gy followed by
30  2 Gy [12]. However, no robust correlation was established
between Cer and radiotherapy efficacy because of the small num-
ber of patients (11 in total) and the diversity of tumours.
During a phase II trial of hypofractionated SBRT combined with
irinotecan chemotherapy, we measured plasma Cer levels in
patients with liver and lung oligometastases originating from pri-
mary colon tumours. The objective was to validate plasma Cer as
an early biomarker of treatment efficacy by correlating variations
in Cer levels during treatment with long-term tumour response.
Materials and methods
Patient eligibility
Biological samples were collected from an ancillary study of a
phase II clinical trial (EudraCT 2006-005440-87; clinical trial
NCT01220063) performed from 2008 to 2013 by 3 French oncology
centres (Nantes, Lyon and Lille). The main objective of the phase II
clinical study (Table 1) was to test the feasibility of SBRT in combi-
nation with irinotecan chemotherapy for colorectal adenocarci-
noma lung and liver metastases. The clinical follow-up is still
ongoing and will be published separately.Treatment planning and delivery
A phase II clinical trial (EudraCT 2006-005440-87; clinical trial
NCT01220063) of SBRT and concomitant irinotecan chemotherapy
for colorectal adenocarcinoma lung and liver metastases was per-
formed from 2008 to 2013 in 3 oncology centres in France (Nantes,
Lyon and Lille). Patient inclusion criteria were inoperable or recur-
rent hepatic and/or lung metastases after surgery, relapse after flu-
orouracil treatment with or without eloxatin or irinotecan, life
expectancy >6 months, measurable metastases (largest diameter
66 cm, sum of the maximum diameter of multiple metastases
66 cm), a clinical target volume (CTV) located more than 12 mm
laterally or 15 mm in the cranio-caudal direction of the stomach,
small intestine, oesophagus, trachea, and pulmonary arteries, and
an adequate haematologic cell pool and adequate hepatic and renal
functions to receive irinotecan. Exclusion criteria were a
performance index >2 (World Health Organization scale), prior
thoraco-abdominal irradiation, a contraindication to irinotecan,Table 1
Patient characteristics and demography.
Location
Lung Liver
Patient (number) Male 8 21
Female 1 5
Age (year) Median 65 66.5
Youngest 32 33
Oldest 77 84
Tumour diameter (mm) Median 13 36
Smallest 4 11
Largest 26 100prior (within 5 years) or concomitant treatment of an invasive can-
cer, diffuse metastatic disease, or more than 3 metastases. The
ethics committees of all 3 institutions approved the protocol, and
signed informed consent was obtained from all patients.
Treatment protocol is described in Fig. S1. Radiotherapy con-
sisted in 4 fractions of 10 Gy delivered on days (D) 1, 3, 8 and 10
using linear accelerator-based devices (Novalis, Brain Lab, Feld-
kirchen, Germany, or Cyberknife, Accuray, Sunnyvaley, CA). In each
case, 99% of the CTV was encompassed by the 75–95% isodose lines
corresponding to a 42–53 Gy dose at the target centre. Irinotecan
(40 mg/m2) (Pfizer, New York, NY) was intravenously injected
30–90 min before delivery of the first and third radiotherapy
fractions.Response criteria
As decided in 2008, tumour response was assessed, using
RECIST 1.1 (Response Evaluation Criteria In Solid Tumors) on chest
or liver CT-scans, 3, 6, and 12 months post-treatment [13]. A com-
plete response (CR) was defined by the disappearance of all target
lesions, a partial response (PR) as a >30% decrease in the sum of the
largest diameter (LD) of target lesions, progressive disease (PD) as a
>20% increase of the LD of each lesion, and stable disease (SD) as
neither sufficient shrinkage to qualify for PR nor sufficient increase
to qualify for PD.Plasma biocollection
Blood samples (20 ml) were collected in sodium citrate tubes
before the first (D0) and after 30 min the second (D3) and fourth
(D10) fractions (Fig. S1), stored at 4 C for 30 min, then centrifuged
at 1000 g for 5 min at 4 C. The plasma aliquots were stored at
80 C until analysis.Cer extraction, purification and analysis
Ultrapure standards of 12 Cer subspecies (C14:0, C16:1, C16:0,
C18:1, DHC18:0, C18:0, C20:1, C20:0, C22:1, C22:0, C24:1 and
C24:0) and non-natural C17:0 Cer used as an internal standard
were purchased from Avanti Polar Lipids (Alabaster, AL). UPLC
grade methanol and analytical grade organic solvents were pur-
chased from Fisher Scientific (Pittsburgh, PA). Forty microlitres of
1 lM C17:0 Cer were added to each plasma sample. Lipids were
extracted from 100 ll of plasma samples in two steps using a pre-
viously described procedure with minor modifications [14]: (1)
addition of 1.5 ml of a acidified hexane/propan-2-ol mixture
(60:40, v/v), vortexing, centrifugation at 3000g for 5 min at 4 C
and collection of the upper phase; (2) addition of 1.5 ml of acidified
methanol, homogenization, centrifugation at 8000g for 5 min at
4 C, and collection of the upper phase. The organic phases from
steps 1 and 2 were combined, dried under nitrogen at room tem-
perature and resuspended in 150 ll of hexane/propan-2-ol
(60:40 v/v).
The lipid extract was purified using an optimized published
method [15]. Briefly, samples were loaded on 100-mg LC-NH2 car-
tridges (Interchim, Montluçon, France) preconditioned with 2 ml of
hexane. The cartridges were washed first with 1.4 ml of ethyl acet-
ate–hexane 15:85 (v/v) to elute neutral lipids in a single fraction,
then with 1.6 ml of chloroform/methanol 23:1 (v/v) to elute free
Cer. The Cer fraction was dried under nitrogen and dissolved in
300 ll of MeOH containing 10 mM highest grade ammonium acet-
ate (Fluka, Buchs, Switzerland) and 0.2% formic acid. Samples were
stored at 20 C until analysis.
Purified Cer fractions were analysed by liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC–ESI-MS/
MS) on an Acquity H-Class UPLC system combined with a Xevo
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Milford, CT). Gradient chromatographic separation was performed
on a Waters C18 BEH column (2.1 mm  50 mm, 1.8 lM particle
size, 0.5 lM prefilter, column heater at 43 C). The mobile phases
consisted of MiliQ water containing 0.2% formic acid and 10 mM
ammonium acetate (Eluent A) and methanol containing 0.2% for-
mic acid and 10 mM ammonium acetate (Eluent B). The injection
volume was 5 ll. Purified Cer were eluted in 4 min with a linear
gradient of 95–98% of eluent B (flow rate: 0.6 ml/min). Before the
next elution, the column was re-equilibrated from 4.00 to
4.10 min and stabilized from 4.10 to 6 min with 95% of eluent B.
All analyses were performed using electrospray ionization in the
positive ion mode with multiple reactions monitoring. Data were
acquired and analysed by Mass-Lynx software version 4.1. Integra-
tion and quantification were performed using Waters Target
LinksTM software. For every dosage, calibration curves were deter-
mined with a mixture of ceramide containing various fatty acid
chain length (C14:0 Cer, C16:0 Cer, C18:0 Cer, C18:1 Cer, C20:0
Cer, C24:0 Cer, and C24:1 Cer). A linear relationship between ana-
lyte response and concentration has been demonstrated by the lin-
ear standard curves obtained in the tested calibration range (0.15–
25 pmol) for all ceramide compound (r > 0.98). The reproducibility
of the plasma ceramide quantification was controlled by perform-
ing the average of three extractions with two LC–MS/MS injections
for each sample. Coefficients of variation (CVs) were less than 10%
for each plasma ceramide compound. Furthermore, an internal
standard (C17:0 ceramide) was included in each sample (calibra-
tion point and plasma) and subjected to extraction and purification
step, allowing a better quantification and the comparison between
every sample.Statistical analysis
Three replicate Cer measurements were performed on each
plasma sample. Comparisons were made using Wilcoxon’s
signed-rank test and ANOVA with 95% confidence intervals (Stat-
View 6.0). Cer variations between D3 or D10 and D0 for every
patient were compared to the expression profiling of other patients
by hierarchical clustering using Cluster [16] and Java TreeView
softwares (http://bonsai.hgc.jp/~mdehoon/software/cluster/).
Independence of groups was established by a Chi-squared test.
Probability curves for tumour control were obtained by the
Kaplan–Meier [17] and compared by the log–rank test. Hazard
ratio (HR) of tumour control was assessed for groups with
increased Cer vs. decreased Cer at D3 and 10. Prognostic value of
variables (sex, age, tumour location and volume) was assessed
using Cox’s multivariate regression model [18]. P values smaller
than 0.05 were considered statistically significant.
Results
Thirty-five patients (mean age, 64 years; range, 32–84; Table 1)
met the inclusion criteria and received the complete treatment.
There were 10 CR, 8 PR, 8 SD, and 9 PD.Correlation between variations in total plasma Cer and tumour
response
At D3, total plasma Cer was significantly increased over basal
Cer level (D0) in patients with CR or PR (CR: 18.5% ± 8.92,
P < 0.05; PR: 10.7% ± 2.27; P < 0.01), remained unchanged in
patients with SD (1.70% ± 4.36, P > 0.05), and fell significantly in
patients with PD (19.06% ± 5.72; P < 0.05) (Fig. 1A). At D10, Cer
remained elevated in patients with CR or PR, but decreased signif-
icantly in patients with SD (15% ± 2.40; P < 0.01) to reach a level
approaching that of patients with PD (20.16% ± 3.71; P < 0.01).The observed increases in total Cer level were not related to any
covariate (patient sex and age, tumour location and volume; data
not shown). Responders were defined either as CR + PR + SD or as
objective responders (patients with tumour shrinkage, i.e. CR
+ PR), with both definitions yielding similar results. According to
the first definition, total Cer was significantly higher than the basal
level at D3 (9.91% ± 3.99; P < 0.05), but not at D10 (2.41% ± 4.6;
P > 0.1; Fig. 1B). In refractory patients (defined as PD), total Cer
was significantly decreased on both of these days (D3:
19.06% ± 5.72, P < 0.05; D10: 20.17% ± 3.71, P < 0.01). According
to the second definition, total Cer level was also significantly
higher than the basal level at D3 in objective responders
(15.07% ± 5.02; P < 0.01) but not at D10 (10.35% ± 5.65; P > 0.5;
Fig. 1C). It was significantly lower in non-responders (SD + PD)
both at D3 (9.79% ± 4.12, P < 0.05) and D10 (17.95% ± 2.27,
P < 0.01). At the difference to the follow-up during the treatment,
basal levels of total plasma Cer were unable to discriminate
between responders and non-responders (objective responders:
3.34 lM ± 0.32, non-responders: 3.82 lM ± 0.45; P = 0.67; Fig. 3A).
Finally, growth of new metastases at distance to the irradiation
location was similar independently of the tumour response of the
patient (4/10 CR; 3/8 PR; 3/8 S; 4/9 PD) and was not correlated
to Cer modulation at D3 or D10 (respectively, P = 0.5 and 0.79,
Fig. S2B).Correlation between variations in Cer subspecies and tumour response
Among the 12 investigated Cer subspecies, the most abundant
were the 4 containing fatty acids C24:0 (44.39% ± 6.91), C24:1
(23.74% ± 6.43), C22:0 (16.06% ± 2.27), and C16:0 (7.51% ± 2.58).
Three others (C18:0, C20:0, C22:1) were present in very small
amounts (respectively 2.11% ± 0.86, 3.09% ± 1.91, 3.06% ± 1.99).
The remaining 5 subspecies were undetectable. The patterns
describing the changes in the levels of the 4 major Cer subspecies
at D3 and D10 were very close to each other and to total Cer
(Fig. 2A–D). For the most abundant subspecies (C24:0), the per-
centage increase over the basal value in objective responders was
11.9% ± 5.17 (P < 0.05) at D3. The percentage decrease in non-
responders was 11.08% ± 4.33 (P < 0.05) at D3 and
19.19% ± 2.39 (P < 0.05) at D10 (Fig. 2C).Hierarchization clustering of patients according to total plasma Cer
Clustering of patients according to the percentage change in
total Cer level at D3 and D10 is shown in Fig. 3. Objective respon-
ders (8/10 CR and 6/8 PR) tended to be clustered above the median
value (P < 0.01) and non-responders (5/8 SD and 8/9 PD) below the
median value (P < 0.01). Measurement of changes in the levels of
the 4 main Cer subspecies did not improve discrimination (data
not shown).Relationship between variations in Cer levels and tumour control at
one year
Tumour volume was measured at 3, 6 and 12 months post treat-
ment. Kaplan–Meier curves revealed that the probability of tumour
control during the first year was high in patients with increased
total plasma Cer levels. Estimation of the treatment efficacy was
better at D10 with HR = 0 (95% CI: 0.044–0.58, P < 0.01), than at
D3 with HR = 0.18 (95% CI: 0.048–0.56, P < 0.01; Fig. 4A and B).
No patient with increased Cer at D10 showed a tumour volume
development during the first year after treatment. Conversely,
patients with decreased Cer have a 50% likelihood of showing a
volume increase, and this risk is similarly at D3 with HR = 5.56
(95% CI: 1.76–21.71, P < 0.01) and D10 with HR = 6.21 (95% CI:
1.57–24.53, P < 0.01).
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Fig. 1. Variations in total plasma Cer according to tumour response. Percentage change in Cer level at D3 and D10 (A) in patients with a complete response (CR), partial
response (PR), stable disease (SD) and progressive disease (PD), (B) in responders (CR + PR + SD) versus refractory patients (PD), (C) in objective responders (CR + PR) versus
non-responders (SD + PD). (Triplicate measurements, number of patients in parentheses, mean ± SEM, ns = P > 0.05, ⁄ = P < 0.01).
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Fig. 2. Variations in the 4 main Cer subspecies according to tumour response. Percentage change in subspecies Cer levels at D3 and D10 (C16:0 (A), C22:0 (B), C24:0 (C) and
C24:1 (D)), in objective responders (CR + PR) versus non-responders (SD + PD). (Triplicate measurements, number of patients in parentheses, mean ± SEM, ns = P > 0.05,
⁄ = P < 0.05).
232 Plasma ceramide correlates with SBRT efficacyDiscussion
In our ancillary study of a phase II trial of SBRT testing with
irinotecan against liver or lung metastases from colorectal cancer,
plasma Cer levels were higher in patients than in healthy donors
(data not shown), in line with published data on changes in Cerlevels in a variety of diseases [8–11]. Total Cer levels before ther-
apy were not indicative of tumour response. However, a significant
increase in plasma Cer was recorded in objective responders unlike
in non-responders early during the course of treatment. There was
a correlation between elevated Cer levels at D3 or D10 of treatment
and tumour response and between reduced Cer levels and stable or
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Fig. 3. Hierarchization clustering of patients according to total plasma Cer at D3
and D10. The position of each patient in the hierarchical tree for each response
category (CR, PR, SD, PD) was obtained by Cluster 3.0 analysis and TreeView
visualization. (Cer increase in red, Cer decrease in green, median 0 value in black).
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patients based on Cer levels which clearly discriminated between
responders and non-responders. No variate (patient sex or age,
tumour location or volume, number of metastases outside of irra-
diation field) correlated with elevated plasma Cer during treatment
(data not shown). In Kaplan–Meier analyses, tumour control was
function of plasma Cer elevation or reduction, with better esti-
mates obtained for measurements made at D10 than D3. One year
after treatment, there was any increase in tumour volume in
patients with elevated Cer at D10 whereas 50% of patients with
decreased Cer at D10 experienced an increase in tumour volume.
Changes in total plasma Cer levels may thus constitute an early
biomarker of tumour response to SBRT combined with irinotecan.
RECIST 1.1 has become a standard methodology for assessing
definitive tumour response following radiotherapy [13]. However,
accuracy has been challenged to detect lung tumour recurrence
after hypofractionned radiotherapy. Target lesion may actually
present fibrosis, and response might be miscategorized [19], so
that tumour efficacy of SBRT with irinotecan is underestimated.
However, the size of mass-like consolidation observed for lung
tumours varied within 12 months after SBRT [20]. After 12 months,
the size did not increase in all of the radiation-induced local injurycases, and has already increased in all recurrence cases. Finally, no
quantitative method using only CT-scan permitted a robust and
definitive estimation of the tumour volume. Again, future studies
must include multimodal imaging, including PET-Scan and RMI.
In our study, we may underestimate the efficacy of the SBRT with
irinotecan, when tumour is showing stabilized volume one year
after treatment. In SD group, some of the 8 patients may be respon-
ders, but the fibrosis on the tumour location does not permit to
observe tumour regression. However, all SD are showing a slight
decrease of ceramide and are ranked for high risk of tumour
escape. Limit of RECIST 1.1 is comforting this statement. Those
patients must be tightly followed-up with novel imaging
modalities.
Our results expand on earlier observations in a small study
demonstrating a significant increase in plasma Cer levels 72 h after
SFGRT (1  15 Gy followed by 30  2 Gy) in 3/3 CR and 2/4 PR
patients but detecting no correlation in non-responders (one
increase and one decrease in level) [12]. The study was inconclu-
sive because of the small number of patients (n = 11), and the
diversity of tumours. Our study in 35 patients (18 responders
and 17 non-responders) included only patients with metastases
derived from primary colorectal carcinomas, receiving the same
treatment and presenting tumours with a well-defined volume
(largest diameter <6 cm), thereby limiting bias due to tumour
volume.
In our study, not only total plasma Cer, but the 4 main Cer sub-
species (C16:0, C18:0, C20:0, C22:0, C22:1, C24:0, and C24:1) were
increased in objective responders. In non-responders, there was a
decrease in Cer subspecies that was more manifested at D10 than
D3. The pattern of changes in all Cer subspecies mirrored that in
total Cer, implying that quantification of individual Cer subspecies
would not improve the strength of total Cer as a biomarker.
In preliminary experimental work without added irinotecan,
tumour irradiation in mice induced plasma Cer in a dose-
dependent manner (unpublished data). The mechanisms underly-
ing elevated plasma Cer levels are unclear, but we can offer at least
two possible explanations. First, ASM and Cer are secreted into the
extracellular medium by endothelial cells activated by pro-
inflammatory cytokines including interleukin-b and tumour necro-
sis factor-a [21]. We observed such secretion after irradiation of
primary microvascular endothelial cells HMVEC-L (unpublished
data). According to this hypothesis, Cer release from endothelial
activation would induce Cer-dependent radiosensitization of
tumour cells. Secondly, the elevation in Cer might also be
explained by induction by SBRT of a high level of tumour apoptotic
bodies enriched in Cer. An unregulated increase in Cer might occur
during the late non-reversible stage of cell death induced by DNA
damage [22] and be a marker of radiation-induced cell death.
Use of plasma Cer as an early biomarker of tumour response
may be a function of radiotherapy protocol, and elevated Cer
may only be observable and quantifiable after high dose radiation.
Commonly, radiotherapy protocols, use a fractionated dosing
schedule of 2 Gy daily over several weeks. However, this dose
may not be efficient to induce Cer within irradiated cells. More-
over, if Cer generation is slow, the early increase over baseline
may not be significant. The newer radiotherapy modalities (e.g.
stereotactic radiotherapy, intraoperative radiotherapy, protonther-
apy) that enable improved tumour targeting, dose escalation and
use of fewer fractions might induce higher acute intracellular Cer
levels and/or tumour cell death. Further investigations should
demonstrate if plasma Cer is a large-range biomarker for innova-
tive high-dose, but also conventional radiotherapies.
Plasma Cer need other complementary studies before being
fully validated as a large broad biomarker of the radiotherapy effi-
cacy. In this present manuscript, Cer analysis has been made on
well-defined patients with lung or liver oligometastases from pri-
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Fig. 4. Kaplan–Meier curves for tumour control over 1 year according to whether an increase or decrease in total plasma Cer at D3 (A) and D10 (B). (Number of patients in
parentheses, increase vs decrease P 6 0.01 at both D3 and D10). Inserted tables below the graphs indicate the number of patients evaluated by CT-scan for tumour control at
every time point. 3 patients have not been evaluated at 6 months.
234 Plasma ceramide correlates with SBRT efficacymary colon tumours to limit a potential heterogeneity of the
response due to tumour localization or type. Future investigations
must be performed on patients carrying on different tumour types
treated by SBRT protocols. Another limit of our present study is due
to the unclear impact of irinotecan on plasma Cer levels. Ongoing
studies on cultured cells and mice are demonstrating that irradia-
tion alone enhances Cer level in cell medium and plasma. Defini-
tive answer will be provided by starting clinical studies on lung
and liver tumours treated by SBRT without chemotherapy. In con-
clusion, the efficacy of radiotherapy protocols may not be judged
until months after treatment. During this time, refractory patients
may suffer from the complications of high-dose radiotherapy
protocols providing no clinical benefit, do not have access to alter-
native treatments, and may experience tumour progression. Ele-
vated plasma Cer levels early during the course of SBRT
combined with irinotecan were found to be correlated with
tumour response and reduced levels with a lack of response, mak-
ing plasma Cer a potentially useful biomarker. The use of this bio-
marker should help physicians in the capacity to define patients
with high risk of tumour escape to the treatment. Those patients
will need a prompt and systematic post-treatment follow-up by
multimodal imaging, such as MRI or F18-FDG PET scan. Moreover,
the use of plasma Cer as a biomarker has the considerable practical
advantage that plasma samples can be readily obtained throughout
treatment whereas tumour biomarkers used in genomic and pro-
teomic assays require tumour biopsies, which are much more
costly and difficult to access especially if multiple biopsies are
required [23].Grant support
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